肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访

2016-07-04 欧洲肿瘤内科学会 Ann Oncol. 2016 Jul 4.

弥漫性大B细胞淋巴瘤纵隔B细胞淋巴瘤

2016年7月，欧洲肿瘤内科学会(ESMO)发布了结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访指南，目的是针对淋巴结外侵犯的弥漫性大B细胞淋巴瘤提出实践指南和建议，主要内容涉及发病率和流行病学，分子/病理学诊断，分期和风险评估，治疗，随访以及个体化医疗等。

中文标题：

2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访

英文标题：

Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

发布机构：

欧洲肿瘤内科学会

发布日期：

2016-07-04

简要介绍：

2016年7月，欧洲肿瘤内科学会(ESMO)发布了结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访指南，目的是针对淋巴结外侵犯的弥漫性大B细胞淋巴瘤提出实践指南和建议，主要内容涉及发病率和流行病学，分子/病理学诊断，分期和风险评估，治疗，随访以及个体化医疗等。




相关资料下载：
[AttachmentFileName(sort=100, fileName=2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访)] GetToolGuiderByIdResponse(projectId=1, id=1c04f1c00123166f, title=2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访, enTitle=Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up., guiderFrom=Ann Oncol. 2016 Jul 4., authorId=null, author=, summary=2016年7月，欧洲肿瘤内科学会(ESMO)发布了结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访指南，目的是针对淋巴结外侵犯的弥漫性大B细胞淋巴瘤提出实践指南和建议，主要内容涉及发病率和流行病学，分子/病理学诊断，分期和风险评估，治疗，随访以及个体化医疗等。, cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Mon Jul 04 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=2016年7月，欧洲肿瘤内科学会(ESMO)发布了结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访指南，目的是针对淋巴结外侵犯的弥漫性大B细胞淋巴瘤提出实践指南和建议，主要内容涉及发病率和流行病学，分子/病理学诊断，分期和风险评估，治疗，随访以及个体化医疗等。<div><br></div><div><br></div><div><br></div>, tagList=[TagDto(tagId=9536, tagName=弥漫性大B细胞淋巴瘤), TagDto(tagId=100827, tagName=纵隔B细胞淋巴瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=null, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4037, appHits=109, showAppHits=0, pcHits=2404, showPcHits=2099, likes=190, shares=4, comments=4, approvalStatus=1, publishedTime=Thu Jul 07 18:43:03 CST 2016, publishedTimeString=2016-07-04, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Thu Jul 07 18:43:03 CST 2016, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 08:29:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访)])
2016 ESMO临床实践指南：结外弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔B细胞淋巴瘤的诊断，治疗和随访
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=248435, encodeId=473d2484352d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Sep 28 07:12:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105276, encodeId=198a1052e6b7, content=先下手为强?，学习学习，参考相关知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Aug 27 05:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92358, encodeId=0c7d92358c8, content=挺不错的?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Fri Jul 08 11:53:00 CST 2016, time=2016-07-08, status=1, ipAttribution=)]
    2017-09-28 覃医生

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=248435, encodeId=473d2484352d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Sep 28 07:12:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105276, encodeId=198a1052e6b7, content=先下手为强?，学习学习，参考相关知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Aug 27 05:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92358, encodeId=0c7d92358c8, content=挺不错的?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Fri Jul 08 11:53:00 CST 2016, time=2016-07-08, status=1, ipAttribution=)]
    2016-08-27 zibozhouping

    先下手为强?，学习学习，参考相关知识

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=248435, encodeId=473d2484352d, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/fFgUJknhibCy1mxLxGwk0ndVfWXmBh8AOibSFDqsSgnoeicu2QjNDYn0g/0, createdBy=c24f1943525, createdName=覃医生, createdTime=Thu Sep 28 07:12:00 CST 2017, time=2017-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105276, encodeId=198a1052e6b7, content=先下手为强?，学习学习，参考相关知识, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160601/IMG574E13FEE55F33222.jpg, createdBy=929c1478678, createdName=zibozhouping, createdTime=Sat Aug 27 05:45:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92358, encodeId=0c7d92358c8, content=挺不错的?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/04/25/ba882cb566d3be250a05e2a69b80f2c9.jpg, createdBy=32881678798, createdName=小M医师, createdTime=Fri Jul 08 11:53:00 CST 2016, time=2016-07-08, status=1, ipAttribution=)]
    2016-07-08 小M医师

    挺不错的?

    0

相关指南

2016 BCSH指南：弥漫性大B细胞淋巴瘤的管理

英国血液学标准委员会(BCSH,British Committee for Standards in Haematology) · 2016-05-16